IPCALAB Share Price Performance
₹1,443.20
159.70 (12.44%)
24.8% undervalued intrinsic discount
₹1,918.00
Fair Value
Price ₹1,443.20
AnalystHighTarget ₹1,918.00
AnalystConsensusTarget ₹1,462.56
AnalystLowTarget ₹982.92
Fair Value₹1,918.00
Share Price₹1,443.20
24.8% undervalued intrinsic discount
IPCALAB Community Narratives
AN
Fair Value ₹1.92k 24.8% undervalued intrinsic discount
Emerging Markets In Asia And Africa Will Fuel Healthcare Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹1.46k 1.3% undervalued intrinsic discount
Expansion Into Flexicare And Dermatology Will Strengthen Future Performance
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value ₹982.92 46.8% overvalued intrinsic discount
Rising Regulations And Cost Pressures Will Limit Pharma Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
IPCALAB Community Fair Values
- ₹1.92kFV24.8% undervalued intrinsic discount13.12%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative12 days ago author updated this narrative
- AN
Consensus Narrative from 17 AnalystsExpansion Into Flexicare And Dermatology Will Strengthen Future Performance
Key Takeaways Significant growth in domestic formulations and strategic new verticals suggest strong future revenue and earnings potential. Improved EBITDA margins and operational efficiencies indicate robust net margins and future earnings growth opportunities.₹1.46kFV1.3% undervalued intrinsic discount11.00%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative2users have followed this narrative5 days ago author updated this narrative - ₹982.92FV46.8% overvalued intrinsic discount10.69%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative12 days ago author updated this narrative
Recent IPCALAB News & Updates
No updates
Ipca Laboratories Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 11, 2025
- Earnings per share (EPS)
- 29.08
- Gross Margin
- 65.54%
- Net Profit Margin
- 8.25%
- Debt/Equity Ratio
- 15.5%
Ipca Laboratories Limited Competitors
About IPCALAB
- Founded
- 1949
- Employees
- 16778
- CEO
- WebsiteView website
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Indian Market Performance
- 7 Days: 0.2%
- 3 Months: 5.2%
- 1 Year: -2.4%
- Year to Date: -1.1%
Over the last 7 days, the market has dropped 1.6%, driven by a pullback of 2.1% in the Financials sector. The market has dropped 6.5% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading